Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $320.00 by Analysts at The Goldman Sachs Group

Key Points

• Goldman Sachs cut Alnylam Pharmaceuticals’ price target to $320 from $536 while maintaining a “buy” rating, implying roughly 88% upside from the prior close.
• Analyst sentiment remains generally positive but has moderated: MarketBeat reports a “Moderate Buy” consensus and a $328.23 average target, while several firms recently lowered their targets or ratings.
• Alnylam’s latest quarter exceeded expectations, with $16.26 in EPS and $1.46 billion in revenue, but the stock traded near its 12-month low amid concerns about slower U.S. Amvuttra demand and moderating sales growth.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target reduced by stock analysts at The Goldman Sachs Group from $536.00 to $320.00 in a report released on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's price target would indicate a potential upside of 88.16% from the stock's previous close.

ALNY has been the subject of several other research reports. JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an "overweight" rating for the company in a research note on Wednesday, September 30th. HC Wainwright reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Bank of America reissued a "buy" rating and set a $287.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Weiss Ratings restated a "hold (c)" rating on shares of Alnylam Pharmaceuticals in a report on Thursday. Finally, Raymond James Financial lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and decreased their target price for the company from $420.00 to $315.00 in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $328.23.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $3.93 during trading hours on Friday, hitting $170.07. 3,012,678 shares of the stock were exchanged, compared to its average volume of 1,499,062. The stock has a 50-day simple moving average of $237.78 and a 200-day simple moving average of $287.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals has a 12 month low of $167.16 and a 12 month high of $479.79. The stock has a market cap of $22.76 billion, a price-to-earnings ratio of 31.60 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.90 earnings per share. Analysts anticipate that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the business's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock valued at $635,296,000 after purchasing an additional 174,482 shares during the period. Legal & General Group Plc acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Alnylam Pharmaceuticals by 7.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company's stock valued at $219,104,000 after acquiring an additional 50,329 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $148,128,000. Finally, Swiss National Bank raised its stake in Alnylam Pharmaceuticals by 7.9% during the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company's stock worth $128,285,000 after buying an additional 28,520 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.